Nano Drug Research Articles

The Application of Nano Drug Delivery Systems in Female Upper Genital Tract Disorders.

The prevalence of female reproductive system disorders is increasing, especially among women of reproductive age, significantly impacting their quality of life and overall health. Managing these diseases effectively is challenging due to the complex nature of the female reproductive system, characterized by dynamic physiological environments and intricate anatomical structures. Innovative drug delivery approaches are necessary to facilitate the precise regulation and manipulation of biological tissues. Nanotechnology is increasingly considered to manage reproductive system disorders, for example, nanomaterial imaging allows for early detection and enhances diagnostic precision to determine disease severity and progression. Additionally, nano drug delivery systems are gaining attention for their ability to target the reproductive system successfully, thereby increasing therapeutic efficacy and decreasing side effects. This comprehensive review outlines the anatomy of the female upper genital tract by highlighting the complex mucosal barriers and their impact on systemic and local drug delivery. Advances in nano drug delivery are described for their sustainable therapeutic action and increased biocompatibility to highlight the potential of nano drug delivery strategies in managing female upper genital tract disorders.

Introduction of Novel Drug Shipping Gadget Nanocapsule

Nano drugs are vesicular structures in which the medicine is contained in a hollow with an inner liquid middle and a polymeric membrane surrounding it . A Nano pill is nanoscale shall made from a secure polymer Nano pill consists of a thin membrane surrounding a middle (Liquid, stable) with their length starting from 10nm to one thousand nm. Nano capsules are submicroscopic colloidal drug provider structures composed of an oily or an aqueous middle surrounded via a skinny polymer membrane. The membrane can be composed of natural or artificial polymers. Kinds of polymers can be hired inside the manufacture of Nano tablets. 1) Polymers discovered in nature 2) Polymers that have been synthesized . a) Solvent evaporation b) Nano precipitation c) emulsification / Solvent diffusion d) Salting out e) Dialysis f) incredible vital fluid era are some of the strategies used to create nano pills. The nanometric length of Nano capsule may be exciting for many programs like cosmetics, perfumes or pharmaceutical industries. this text is an prolonged overview of these Nanocapsule technologies and their applications for the remedy of diverse diseases. The Nanocapsule is used in various fields for drug transport in case of tumors, as a Nano capsule Bandages to combat infection, as a liposomal Nanocapsule in meals technology and Agriculture, in turning in radio remedy and as a self-recovery material. Nano capsules are subjected to a diffusion of characterization and evaluation methods. To attain managed launch and efficient drug focused on, dispersed polymer nanocapsules can be employed as nano-sized drug providers. Nanocapsules variety in length from 10 nm to a thousand nm and are available in a selection of sizes. Nanocapsule is a Nanoparticle that is spherical, hole shape with a diameter much less than 200nm in which favored substance may be placed. They may be packed with a solvent, both polar or non polar.

Enhancing chemoimmunotherapy for colorectal cancer with paclitaxel and alantolactone via CD44-Targeted nanoparticles: A STAT3 signaling pathway modulation approach

Chemoimmunotherapy has the potential to enhance chemotherapy and modulate the immunosuppressive tumor microenvironment by activating immunogenic cell death (ICD), making it a promising strategy for clinical application. Alantolactone (A) was found to augment the anticancer efficacy of paclitaxel (P) at a molar ratio of 1:0.5 (P:A) through induction of more potent ICD via modulation of STAT3 signaling pathways. Nano drug delivery systems can synergistically combine natural drugs with conventional chemotherapeutic agents, thereby enhancing multi-drug chemoimmunotherapy. To improve tumor targeting ability and bioavailability of hydrophobic drugs, an amphiphilic prodrug conjugate (HA-PTX) was chemically modified with paclitaxel (PTX) and hyaluronic acid (HA) as a backbone. Based on this concept, CD44-targeted nanodrugs (A@HAP NPs) were developed for co-delivery of A and P in colorectal cancer treatment, aiming to achieve synergistic toxicity-based chemo-immunotherapy. The uniform size and high drug loading capacity of A@HAP NPs facilitated their accumulation within tumors through enhanced permeability and retention effect as well as HA-mediated targeting, providing a solid foundation for subsequent synergistic therapy and immunoregulation. In vitro and in vivo studies demonstrated that A@HAP NPs exhibited potent cytotoxicity against tumor cells while also remodeling the immune-suppressive tumor microenvironment by promoting antigen presentation and inducing dendritic cell maturation, thus offering a novel approach for colorectal cancer chemoimmunotherapy.

Enhanced in vivo Stability and Antitumor Efficacy of PEGylated Liposomes of Paclitaxel Palmitate Prodrug.

The clinical use of paclitaxel (PTX) in cancer treatment is limited by its poor water solubility, significant toxicity, and adverse effects. This study aimed to propose a straightforward and efficient approach to enhance PTX loading and stability, thereby offering insights for targeted therapy against tumors. We synthesized a paclitaxel palmitate (PTX-PA) prodrug by conjugating palmitic acid (PA) to PTX and encapsulating it into liposomal vehicles using a nano delivery system. Subsequently, we investigated the in vitro and in vivo performance as well as the underlying mechanisms of PTX-PA liposomes (PTX-PA-L). PTX had a remarkable antitumor effect in vivo and significantly decreased the myelosuppressive toxicity of PTX. Moreover, the introduction of PA increased the lipid solubility of PTX, forming a phospholipid bilayer as a membrane stabilizer, prolonging the circulation time of the drug and indirectly increasing the accumulation of liposomes at the tumor site. Our in vivo imaging experiments demonstrated that PTX-PA-L labeled with DiR has greater stability in vivo than blank liposomes and that PTX-PA-L can target drugs to the tumor site and efficiently release PTX to exert antitumor effects. In a mouse model, the concentration of PTX at the tumor site in the PTX-PA-L group was approximately twofold greater than that of Taxol. However, in a nude mouse model, the concentration of PTX at the tumor site in the PTX-PA-L group was only approximately 0.8-fold greater than that of Taxol. Furthermore, the originally observed favorable pharmacodynamics in normal mice were reversed following immunosuppression. This may be caused by differences in esterase distribution and immunity. This prodrug technology combined with liposomes is a simple and effective therapeutic strategy with promising developmental prospects in tumor-targeted therapy owing to its ability to convert PTX into a long-circulating nano drug with low toxicity, high pharmacodynamics, and good stability in vivo.

Tumor therapy utilizing dual-responsive nanoparticles: A multifaceted approach integrating calcium-overload and PTT/CDT/chemotherapy

The advancement of rational nano drug delivery systems offers robust tools for achieving synergistic therapeutic outcomes in tumor treatment. In this study, we present the development of pH and near-infrared laser dual-responsive nanoparticles (DOX-CuS@CaCO3@PL-PEG, DCCP NPs) based on calcium carbonate, utilizing a one-pot gas diffusion reaction. These nanoparticles enable combined photothermal therapy (PTT), chemodynamic therapy (CDT), chemotherapy, and Ca2+-overloading synergistic therapy. Doxorubicin (DOX) and copper sulfide (CuS) NPs were co-loaded in CaCO3, followed by PEG surface functionalization. The presence of PEG enhanced the stability of DCCP NPs in aqueous environments. Controlled release of DOX, CuS NPs, and Ca2+ occurs specifically in the acidic tumor microenvironment. Released DOX enhances chemotherapy efficiency, while CuS NPs, upon laser irradiation, induce thermal damage, promoting further drug release and cellular uptake. Additionally, CuS NPs in our system consume excess GSH and generate toxic hydroxyl radicals (·OH) through a Fenton-like reaction, contributing to CDT. These radicals not only directly eliminate tumor cells but also disrupt mitochondrial Ca2+ buffering capacity. Furthermore, Ca2+ released from CaCO3 induces Ca2+-overloading, intensifying mitochondrial disruption and oxidative damage. The synergistic combination of PTT, CDT, chemotherapy, and Ca2+-overloading showcases significant therapeutic potential, indicating broad applications in tumor therapy. This multifaceted approach holds promise for advancing the field of tumor therapeutics.

Enhanced docetaxel therapeutic effect using dual targeted SRL-2 and TA1 aptamer conjugated micelles in inhibition Balb/c mice breast cancer model

Effective targeting and delivery of large amounts of medications into the cancer cells enhance their therapeutic efficacy through saturation of cellular defensive mechanisms, which is the most privilege of nano drug delivery systems (NDDS) compared to traditional approaches. Herein, we designed dual-pH/redox responsive DTX-loaded poly (β-amino ester) (PBAS) micelles decorated with a chimeric peptide and TA1 aptamer. In vitro and in vivo results demonstrated that the designed nanoplatform possessed an undetectable nature in the blood circulation, but after exposure to the tumor microenvironment (TME) of 4T1 breast cancer, it suddenly changed into dual targeting nanoparticles (NPs) (containing two ligands, SRL-2 and TA1 aptamer). The dual targeting NPs destruction in the high GSH and low pH conditions of the cancer cells led to amplified DTX release (around 70% at 24 h). The IC50 value of DTX-loaded MMP-9 sensitive heptapeptide/TA1 aptamer-modified poly (β-amino ester) (MST@PBAS) micelles and free DTX after 48 h of exposure was determined to be 1.5 µg/ml and 7.5 µg/ml, respectively. The nano-formulated DTX exhibited cytotoxicity that was 5-fold stronger than free DTX (Pvalue˂0.001). Cell cycle assay test results showed that following exposure to MST@PBAS micelles, a considerable rise in the sub G1 population (48%) suggested that apoptosis by cell cycle arrest had occurred. DTX-loaded MST@PBAS micelles revealed significantly higher (Pvalue ˂ 0.001) levels of early apoptosis (59.8%) than free DTX (44.7%). Interestingly, in vitro uptake studies showed a significantly higher TME accumulation of dual targeted NPs (6-fold) compared to single targeted NPs (Pvalue < 0.001) which further confirmed by in vivo biodistribution and fluorescent TUNEL assay experiments. NPs treated groups demonstrated notable tumor growth inhibition in 4T1 tumor bearing Balb/c mice by only 1/10th of the DTX therapeutic dose (TD) as a drug model. In conclusion, cleverly designed nanostructures here demonstrated improved anticancer effects by enhancing tumor targeting, delivering chemotherapeutic agents more accurately, promoting drug release, reducing the therapeutic dosage, and lowering side effects of anticancer drugs.

Formulation, Optimization, and Evaluation of Solid-lipid Formulation for Bioavailability Enhancement Utilizing Diltiazem Hydrochloride

Background: Cardiac arrhythmia is a health concern, requiring effective medication for proper treatment. Diltiazem hydrochloride (DTZ.HCL), a class IV anti-arrhythmic calcium channel blocker, was used as a model drug due to its ability to block Ca++ channels in the SA and AV nodes, reducing calcium entry into cardiac cells and subsequently decreasing the force of contraction and oxygen consumption by the heart. Despite its good oral absorption, DTZ.HCL bioavailability is reduced to approximately 40% due to extensive first-pass metabolism. A nano-enabled drug delivery system has the advantage of incorporating both lipophilic and hydrophilic drugs with improved physical stability and enhanced bioavailability. Objective: The objective of this study was to develop a solid-lipid formulation utilizing diltiazem hydrochloride and evaluate it for its bioavailability enhancement. Method: In the experimental study, SLNs were prepared using the microemulsion technique. A blend ratio (1:1) of lipid (stearic acid: compritol 888 ATO), span 80, PEG 200, and water was selected based on the microemulsion region obtained from the Triplot (4.1) ternary phase diagram. The hydrophilic drug diltiazem hydrochloride was incorporated into the lipid blend, and a preheated Smix was maintained at 80°C to obtain a transparent microemulsion, which then crystallized to form SLNs upon subsequent dispersion in cold water (1:25). Critical process parameters, including magnetic stirring speed, homogenizer speed, and probe sonication cycle, were optimized using Design Expert 10 software to achieve the desired particle size diameter, PDI, and entrapment efficiency. Results: The results revealed that the particle size and PDI were significantly influenced by the span 80 and PEG 200. An increase in the concentration of the lipid blend resulted in large particle sizes. The optimized formulation showed a particle size of 415.4±0.2 nm, PDI of 0.184±0.01, and zeta potential of -24.19±0.12 mV. These results were corroborated by DSC thermograms, which indicated reduced enthalpy associated with the reduced particle size of SLNs. Given that diltiazem hydrochloride is a hydrophilic drug with high water solubility, the entrapment efficiency was relatively 30.6% ±0.45. In vitro release studies demonstrated an initial burst release, followed by a sustained release of 85% over 24 hours. The optimized SLNs followed the Higuchi matrix model, with a coefficient of correlation (R²) value of 0.9369. Conclusion: Results concluded successful development of SLNs with improved bioavailability when compared by way of in-vitro method with marketed preparations.

Stiff-Soft Hybrid Biomimetic Nano-Emulsion for Targeted Liver Delivery and Treatment of Early Nonalcoholic Fatty Liver Disease

Background: Nonalcoholic fatty liver disease (NAFLD) poses a risk for numerous metabolic diseases. To date, the U.S. Food and Drug Administration has not yet approved any medications for the treatment of NAFLD, for which developing therapeutic drugs is urgent. Dihydromyricetin (DMY), the most abundant flavonoid in vine tea, has been shown to be hepatoprotective. Its application was limited by low bioavailability in vivo; Methods: In order to improve the bioavailability of DMY and achieve liver-targeted delivery, we designed a DMY-loaded stiff-soft hybrid biomimetic nano drug delivery system (DMY-hNE). The in vivo absorption, distribution, pharmacokinetic profiles, and anti-NAFLD efficacy of DMY-hNE were studied; Results: DMY-hNE was composed of a stiff core and soft shell, which led to enhanced uptake by gastrointestinal epithelial cells and increased penetration of the mucus barrier, thus improving the in vivo absorption, plasma DMY concentration, and liver distribution versus free DMY. In an early NAFLD mouse model, DMY-hNE effectively ameliorated fatty lesions accompanied with reduced lipid levels and liver tissue inflammation; Conclusions: These findings suggested that DMY-hNE is a promising platform for liver drug delivery and treatment of hepatopathy.

Carbon dots-cisplatin nano drug delivery system induces the death of oral tongue squamous cell under self-targeting chemical/photodynamic combined therapy

HypothesisChemotherapy is effective against oral squamous cell carcinoma (OSCC), but its utility is hindered by significant side effects and drug resistance. Photodynamic therapy (PDT) offers a less invasive alternative, but challenges remain due to the hydrophobic nature of most photosensitizers (PS), limiting their effectiveness. A novel nano-composite, combining hyaluronic acid-carbon dots (HA-CDs) with cisplatin (DDP), may overcome these limitations by improving drug hydrophobicity and enabling dual-function therapy. ExperimentsHyaluronic acid-carbon dots (HA-CDs) were synthesized via a hydrothermal method using hyaluronic acid as the primary precursor. The resulting HA-CDs were then combined with cisplatin (DDP) to form the HA-CDs-DDP composite, designed to enhance DDP hydrophobicity and serve as both a chemotherapy agent and a PS. FindingsThe HA-CDs-DDP composite facilitates self-targeting chemotherapy while acting as an intrinsic photosensitizer, eliminating the need for additional PS. The composite generated reactive oxygen species (ROS), effectively inhibiting tumor growth in vivo. This study demonstrates the potential of HA-CDs-DDP to induce cell death in OSCC via a combined chemotherapy/photodynamic therapy pathway, providing a promising new approach for clinical OSCC treatment.

Improving the bioavailability of three-dimensional ZIF-8 MOFs against carbon tetrachloride-induced brain and spleen toxicity in rats

Different traditional medicines have less solubility and low availability in the body. To enhance these properties new technologies are being introduced. Silymarin is a well-known antioxidative drug used against different diseases but has less solubility and bioavailability. In this work to enhance these properties it is loaded in a Cordia myxa plant extract encapsulated green fabricated ZIF-8 framework (CME@ZIF-8). The confirmation of the Sily@ZIF-8 nano drug was done by UV, XRD, FTIR, SEM, TEM, EDS, and ζ-potential. Further, the thermal stability of the samples was analyzed using thermogravimetric analysis. The average measured crystal size from XRD and average grain size of Sily-ZIF-8 nano drug from SEM histogram analysis was 17.23 nm and 515 nm respectively. The in vivo antioxidative potential in the brain and spleen of the prepared nano drug in comparison with pure silymarin was checked in CCl4 intoxicated albino rats with different dosing patterns of 500, 1000, and 1500 μg/kg BW. CCl4 increased TBARS and ROS levels, which induced DNA damage and reduced the CAT, POD, and SOD levels in these tissues. Treating rats with Sily@ZIF-8 restored these biochemical parameters to the normal level. Moreover, the histopathological studies of these tissues demonstrated that Sily@ZIF-8 protected the rat's brain and spleen tissues from oxidative damage and restored normal functions of these tissues. Furthermore, the COMET assay depicted that the level of DNA damage was also mitigated with Sily@ZIF-8 nano-drug. This study suggests that the Sily@ZIF-8 nano drug protects different tissues possibly by mitigating oxidative stress more efficiently than the traditional drug silymarin and could be used in the future.

Application of drug delivery microspheres in cancer therapy

Microspheres are a novel drug delivery system, which provides a new approach for cancer therapy. Anti-cancer agents loaded in microspheres can be released in a controlled and sustained pattern, thereby enhancing the therapeutic efficacy and reducing the side effects and toxicity. The preparation methods for drug delivery microspheres include solvent evaporation, phase separation, spray drying, and microfluidic technology, each of these have advantages and limitations. Based on the preparation materials, drug delivery microspheres can be categorized into natural polymer microspheres, synthetic polymer microspheres and bioceramic microspheres. Natural polymer micro-spheres have good biocompatibility and degradability; synthetic polymer microspheres exhibit superior mechanical properties; bioceramic microspheres have good biocompatibility and specific biological functions, which are widely used in bone tissue engineering. Drug delivery microspheres are used for cancer treatment in various modalities, including photothermal therapy, photodynamic therapy, radioembolization, and immunotherapy, as well as chemotherapy. This article reviews the recent progress of microspheres as nano drug delivery system in cancer treatment to provide a reference for further clinical and translation research.

Mapping the evolution and research landscape of ferroptosis-targeted nanomedicine: insights from a scientometric analysis.

Notable progress has been made in "ferroptosis-based nano drug delivery systems (NDDSs)" over the past 11years. Despite the ongoing absence of a comprehensive scientometric overview and up-to-date scientific mapping research, especially regarding the evolution, critical research pathways, current research landscape, central investigative themes, and future directions. Data ranging from 1 January 2012, to 30 November 2023, were obtained from the Web of Science database. A variety of advanced analytical tools were employed for detailed scientometric and visual analyses. The results show that China significantly led the field, contributing 82.09% of the total publications, thereby largely shaping the research domain. Chen Yu emerged as the most productive author in this field. Notably, the journal ACS Nano had the greatest number of relevant publications. The study identified liver neoplasms, pancreatic neoplasms, gliomas, neoplasm metastases, and melanomas as the top five crucial disorders in this research area. This research provides a comprehensive scientometric assessment, enhancing our understanding of NDDSs focused on ferroptosis. Consequently, it enables rapid access to essential information and facilitates the extraction of novel ideas in the field of ferroptotic nanomedicine for both experienced and emerging researchers.

Graphene-Based Nano Drug Delivery of Curcumin for the Treatment of Dengue Fever.

Graphene, which is defined as a single-layered sp2 hybridized carbon atoms placed in a honeycomb-like crystal lattice when converted to graphene oxide, has proven its worth by showing its tremendous capacity in controlling the release rate of drugs by entrapping in the numerous pockets present inside it through π-π stacking interaction when used as a nanocarrier. In this experiment graphene oxide was synthesized through traditional Hummer’s method and was used as a nanocarrier to target nanosized drugs, which was prepared by loading curcumin drug into the PVP functionalized graphene oxide by using necessary procedures. After the successful confirmation of the stability, functionalization, and compatibility through various characterization procedures and effective drug loading into the systems, the release behavior of the formulations has been checked through dialysis bag diffusion technique using potassium phosphate buffer saline (pH 7.2, 4.0 and 9.2) for selection of the best medium for determination of the successful sustained-release behavior of the drugs through the dialysis membrane which concluded with satisfactory, sustained and constant drug release phenomenon in the acidic environment reflecting an idea of the fact its favorable release in acidic pH. It is a fact known that dengue fever causes systemic acidosis i.e., reduction of the pH of blood below 7. Thus, when used in-vivo there is a possibility that the formulation has easy access to its target and, performs the desired mechanism of action and can be used as a therapeutic delivery system against the Dengue virus.

89Zr PET imaging guided validation of the medicinal potentiality of UiO-66 based nano drug delivery system

89Zr PET imaging guided validation of the medicinal potentiality of UiO-66 based nano drug delivery system

A Review on the Progress of QbD Approach in Nanosystems Optimization: Current Updates and Strategic Applications

: Nanotechnology has made great strides in developing targeted drug delivery systems over the past few decades. These systems have garnered attention for their unique biological properties and ability to deliver drugs in a stable and sustainable manner. Despite these advances, there are still concerns about quality, efficacy, and safety. Many fabrication techniques still need to be refined to address the complex structures and non-standard manufacturing processes that can impact the quality of drug delivery systems. Recently, optimization techniques such as Quality by Design (QbD) have gained popularity in the pharmaceutical industry. QbD is a structured approach that addresses many technological and trait-related issues by providing a deep understanding of the product and its operations. This review examines the current state of QbD in the design of various nano-drug delivery systems, including lipid nanoparticles, lipid carriers, nano micelles, beaded drug delivery systems, nanospheres, cubosomes, and novel cosmeceuticals. Various mathematical models and statistical tests have been used to identify the parameters that influence the physical characteristics of these nanosystems. Critical process attributes such as particle size, yield, and drug entrapment have been studied to assess risk factors during development. However, critical process parameters are often identified through trial and error. This review highlights common material attributes and process parameters that affect the quality of nano-drug delivery systems. Hence, this survey has disclosed the various material attributes and process parameters, quality variables of different nano-drug systems. QbD designs such as Central drug composite, Design of experiment, D-optimal Design, Box-Benkhen Design, and Face center Design in optimizing the nanosystems have also been added. Conclusively, QbD optimization in nano drug delivery systems is expected to be a time-honored strategy in the forthcoming years.

Navigating the Potential of Natural Products through Nano-enabled Drug Deliveries in Mitigation of Cancer: A Review

Navigating the Potential of Natural Products through Nano-enabled Drug Deliveries in Mitigation of Cancer: A Review

Phyto-Active Components Delivered through Lipid Nanodrug Carriers as a Promising Avenue for the Treatment of Alzheimer’s Disease: Their Present Status and Industrial Viability

Introduction: Present years have witnessed an unprecedented growth of Alzheimer’s disease (AD) with limited scope for conventional therapeutics. Plant-derived active components (PACs) are being widely utilized as alternate, compatible, efficacious, eco-friendly strategies to ameliorate therapeutic benefits in AD while minimizing toxic effects. However, delivery of PACs in the regular dosage form often faces challenges due to low stability and bioavailability, brainspecific delivery, dose-related toxic effects, etc., which can be subsided by experimentally fabricated Lipid Nano Drug Carriers (LNCs). The objective of this study is to provide a comprehensive, evidence-based review on recent progress in the PACs-loaded lipid nanocarriers (PLNs)-based therapeutic strategies for AD. Methods: For the study implementation, a systematic literature review was carried out from various scientific potential databases like Scopus, Pubmed, Web of Science, etc., and relevant evidence- based pre-clinical research data was pooled to draw conclusive outcomes. Results: LNCs are treated as promising avenues to effectively deliver various PACs into the brain due to their high lipophilicity with ultra-micron size and tunable surface features, which make them eligible to pass through the blood-brain barrier. Both passive and active targeting of PLNs has been explored to target AD by overcoming the off-target bio delivery problems. Conclusion: The review provided updated preclinical study-based data on the potentialities of PLNs in overcoming AD. Simultaneously, equal weightage was devoted to the issues faced beyond the laboratory in their successful technology transfer. The study would be beneficial in unveiling important insights into the implications of PLNs for their futuristic clinical applicability.

Investigation of Dual-Loaded Doxorubicin and Sorafenib Liposomes Co-Modified with Glycyrrhetinic Acid and Cell-Penetrating Peptide TAT.

Combining Doxorubicin (DOX) with sorafenib (SF) is a promising strategy for treating Hepatocellular Carcinoma (HCC). However, strict dosage control is required for both drugs, and there is a lack of target selectivity. This study aims to develop a novel nano-drug delivery system for the combined use of DOX and SF, aiming to reduce their respective dosages, enhance therapeutic efficacy, and improve target selectivity. DOX/SF co-loaded liposomes (LPs) were prepared using the thin-film hydration method. The liposomes were modified with 1,2-distearoyl-sn-glycero-3-phospho-ethanolamine (DSPE)- polyethylene glycol (PEG2000), DSPE-PEG1000-cell penetrating peptide TAT, and Glycyrrhetinic Acid (GA). The basic properties of the liposomes were characterized. CCK-8 cell viability assays were conducted using HepG2, MHCC97-H, and PLC cell models, and apoptosis experiments were performed using HepG2 cells to determine if this delivery system could reduce the respective dosages of DOX and SF and enhance HCC cytotoxicity. Liposome uptake experiments were performed using HepG2 cells to validate the target selectivity of this delivery system. A GA/TAT-DOX/SF-LP liposomal nano drug delivery system was successfully constructed, with a particle size of 150 nm, a zeta potential of -7.9 mV, a DOX encapsulation efficiency of 92%, and an SF encapsulation efficiency of 88.7%. Cellular experiments demonstrated that this delivery system reduced the required dosages of DOX and SF, exhibited stronger cytotoxicity against liver cancer cells, and showed better target selectivity. A simple and referenceable liposomal nano drug delivery system has been developed for the combined application of DOX and SF in hepatocellular carcinoma treatment.

A Review on Solid Lipid Nanoparticles as Nano Drug Delivery Transporters

Abstract: Solid lipid nanoparticles (SLN) have several potential uses in research for medicine such as drug discovery and drug delivery, an area at the forefront of evolving area of nanobiotechnology. In general, SLNs were created to address the drawbacks of conventional colloidal carriers, including emulsions, liposomes, and polymeric nanoparticles since they provide various advantages such as favourable release profiles and tailored drug delivery with outstanding physical-chemical stability. Solid lipid nanoparticles are spherical solid lipid particles that are distributed in water or an aqueous surfactant solution and are in the nanometer size range. Therefore, SLN is used to deliver hydrophilic and lipophilic drugs. The review article focuses on various aspects of SLN including the structure, the influence of excipients, the drug incorporation model, the principle of release, the method of preparation, characterization, the route of administration and biodistribution, and the application of SLN.

The Many Faces of Cyclodextrins within Self-Assembling Polymer Nanovehicles: From Inclusion Complexes to Valuable Structural and Functional Elements.

Most chemotherapeutic agents are poorly soluble in water, have low selectivity, and cannot reach the tumor in the desired therapeutic concentration. On the other hand, sensitive hydrophilic therapeutics like nucleic acids and proteins suffer from poor bioavailability and cell internalization. To solve this problem, new types of controlled release systems based on nano-sized self-assemblies of cyclodextrins able to control the speed, timing, and location of therapeutic release are being developed. Cyclodextrins are macrocyclic oligosaccharides characterized by a high synthetic plasticity and potential for derivatization. Introduction of new hydrophobic and/or hydrophilic domains and/or formation of nano-assemblies with therapeutic load extends the use of CDs beyond the tried-and-tested CD-drug host-guest inclusion complexes. The recent advances in nano drug delivery have indicated the benefits of the hybrid amphiphilic CD nanosystems over individual CD and polymer components. This review provides a comprehensive overview of the most recent advances in the design of CDs self-assemblies and their use for delivery of a wide range of therapeutic molecules. It aims to offer a valuable insight into the many roles of CDs within this class of drug nanocarriers as well as current challenges and future perspectives.